Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- ?S-(benzoylamino)-?R-hydroxy-benzenepropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
- Correlated keywords
- Microtubules cancers cervical HeLa lung A549 breast MCF-7 colon HT-29 ovarian OVG-1 pancreatic PC-Sh carcinomas chemotherapy mitotic arrest apoptosis JNK BCL-2 p53 Pacific yew tree c-Jun cyclin-dependent kinases multipolar spindle formation Capxol Mitotax Onxal QW 8184 Yewtaxan Tocosol Taxus Liberte Genexol-PM Genetaxyl EndoTAG 1 Ebetaxwl DHP 107 ABI 007 Bristol-Myers Squibb Brand of Paclitaxel Bristol-Myers Brand of Paclitaxel Paclitaxel (4 alpha)-Isomer Lemery Brand of Paclitaxel Ivax Brand of Paclitaxel Bull Brand of Paclitaxel 7-epi-Taxol 7 epi Taxol Paclitaxel NSC-125973 NSC 125973 Bris Taxol NSC125973 Taxol A Anzatax Praxel Paxene Taxol Onxol
- Product Overview:
Paclitaxel, a potent disruptor of microtubules derived from the bark of the Pacific yew tree, is widely used as a chemotherapeutic compound. Tested against a panel of cervical (HeLa), lung (A549), breast (MCF-7), colon (HT-29), ovarian (OVG-1), and pancreatic (PC-Sh) carcinomas, paclitaxel demonstrates IC50 values ranging from 2.5-7.5 nM.{18505} Paclitaxel disrupts multipolar spindle formation, inducing cell cycle arrest in various human cell cancer lines (IC50s = 6.7-18.5 nM) at both prophase and G1.{18494} It initiates apoptosis of cancer cells through multiple mechanisms involving p53-dependent and -independent pathways, Bcl-2 family members, cyclin-dependent kinases, and c-Jun N-terminal kinases/stress-activated protein kinases.{18495}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.